Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
McKesson
Express Scripts
Colorcon
Boehringer Ingelheim

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR DALVANCE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Dalvance

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02269644 ↗ A P3 Comparator Trial in Community Acquired Bacterial Pneumonia Withdrawn Durata Therapeutics Inc., an affiliate of Allergan plc Phase 3 2015-11-01 This study will be a double-blind, randomized, multicenter trial to assess the safety and efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of azithromycin in comparison to an approved antibiotic regimen of linezolid 600 mg every 12 hours for 10-14 days plus a single 500 mg IV dose of azithromycin for the treatment of Community Acquired Bacterial Pneumonia.
NCT02344511 ↗ Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Withdrawn Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) Phase 3 2016-03-01 Dalbavancin for Pediatric Osteomyelitis
NCT03372941 ↗ Hospital Avoidance Strategies for ABSSSI Terminated Allergan Phase 4 2019-03-04 More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources.
NCT03372941 ↗ Hospital Avoidance Strategies for ABSSSI Terminated The Foundation for Barnes-Jewish Hospital Phase 4 2019-03-04 More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources.
NCT03372941 ↗ Hospital Avoidance Strategies for ABSSSI Terminated Washington University School of Medicine Phase 4 2019-03-04 More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dalvance

Condition Name

Condition Name for Dalvance
Intervention Trials
Gram-Positive Bacterial Infections 2
Osteomyelitis 2
Prosthetic Joint Infection 1
Septic Arthritis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dalvance
Intervention Trials
Infection 4
Infections 4
Communicable Diseases 3
Gram-Positive Bacterial Infections 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dalvance

Trials by Country

Trials by Country for Dalvance
Location Trials
United States 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dalvance
Location Trials
Colorado 1
Virginia 1
Missouri 1
Montana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dalvance

Clinical Trial Phase

Clinical Trial Phase for Dalvance
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dalvance
Clinical Trial Phase Trials
Withdrawn 2
Not yet recruiting 1
Recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dalvance

Sponsor Name

Sponsor Name for Dalvance
Sponsor Trials
Washington University School of Medicine 1
Johns Hopkins University 1
Infectious Diseases Physicians, Inc. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dalvance
Sponsor Trials
Other 6
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
Dow
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.